Some drugs are going generic this year and next

August 3, 2012 By Alexia Elejalde-Ruiz

Dozens of brand-name prescription drugs are losing their patent protection, allowing generic versions to enter the market and consumers to save 30 to 80 percent on those medications, said David Belian, director of media relations for the Generic Pharmaceutical Association.

Generic forms of drugs have the same active ingredients as their brand-name counterparts but are significantly cheaper because they don't invest in clinical trials or advertising, Belian said.

About 80 percent of prescriptions are filled with generic drugs, and they have a good track record, said Howard Schiff, executive director of the Maryland Pharmacists Association. But some generic drugs may not work as well as the original brands, so before making the switch consider consulting your doctor who can write a prescription specifying brand-name or generic, Schiff said.

These are the prescription drugs that have been or are expected to be released as generics in 2012 and 2013, according to , which manages pharmacy benefits for employer health plans.

2012: Symbyax (treatment-resistant depression); Geodon (schizophrenia, bipolar disorder); Lexapro (depression, anxiety); Seroquel (schizophrenia, bipolar disorder); Avandia (Type 2 diabetes); Avandamet (Type 2 diabetes); Avandaryl (Type 2 diabetes); Avapro (high blood pressure); Avalide (high blood pressure); Provigil (excessive sleepiness); Plavix (prevents blood clots); Viramune (HIV infection); Lescol/Lescol XL (high cholesterol); Tricor (high cholesterol); Clarinex/Clarinex D (, hives); Singulair (asthma and allergy symptoms); Actos (Type 2 diabetes); Xopenex (asthma, COPD); Revatio (); Diovan/Diovan HCT (high blood pressure); Detrol (); Lidoderm (pain from post-herpetic neuralgia); Atacand/Atacand HCT (); Evoxac (Sjogren's syndrome); Maxalt/Maxalt MLT (migraines); Actoplus Met (Type 2 diabetes).

2013: Opana ER (pain); Zometa (bone complications from cancer); Valcyte (viral infections); Zomig (migraines); Fosamax Plus D (osteoporosis); Rilutek (amyotrophic lateral sclerosis); Temodar (glioblastoma multiforme); Cerezyme (Gaucher disease); Niaspan (high cholesterol); Advicor (); AcipHex (GERD); Vivelle-DOT (menopausal symptoms); Cymbalta (depression, anxiety, nerve/musculoskeletal pain, fibromyalgia).

Explore further: Americans turn to generic medications in 2010: report

Related Stories

Americans turn to generic medications in 2010: report

April 22, 2011
(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Global spending on drugs to slow through 2016

July 12, 2012
(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

Drug prices to plummet in wave of expiring patents

July 25, 2011
The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol ...

FDA approves first generic versions of Zyprexa

October 24, 2011
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

Generic boniva approved for osteoporosis

March 19, 2012
(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Osiris1
not rated yet Aug 12, 2012
Fosamax will disappear in the wave of lawsuits against its manufacturer. No generic manufacturer in his right mind would ever touch that poison.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.